BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit
  is the definitive industry-led forum for drug development in the largest
  solid tumor indication. This is a strategic conference designed to bring
  drug development teams together to address critical challenges surroundi
 ng therapeutic potency\, tumor resistance and relapse and expanding the c
 linical utility of targeted and immuno-therapies\, either in combination 
 or monotherapies.\n\nArriving at a critical point for the NSCLC drug deve
 lopment field\, as checkpoint inhibitors are on the brink of entering the
  perioperative setting and the approval of novel bispecifics with dual on
 cogenic targeting\, this forum will enable you to see a full picture of t
 he clinical trial landscape and identify what MoAs and targets future bio
 pharma investment will be put towards.\n\nNetwork with 100+ executive bio
 pharma leaders over 3-days of comprehensive insights to uncover the lates
 t industry knowledge on the molecular heterogeneity of lung cancer\, the 
 implications for therapeutic design when considering acquired resistance 
 and optimal application of new drugs in the clinic.\n\nJoin global innova
 tors to:Leverage the knowledge gained from the current EGFR-TKI successes
  to implement it into strategies for improvement\, best application strat
 egies and potential combination partners with AstraZeneca\, Puma Biotechn
 ology\, Cullinan Oncology and TakedaUnravel the potentials of targeting c
 urrently untreatable acquired resistances through small molecules and bio
 logics to develop novel agents against mutations with AbbVie\, Merus\, Bl
 ack Diamond\, AOM Biosciences and Mirati Therapeutics.Dive into the excit
 ing advancements in the NSCLC rare mutations space\, with the novel thera
 pies in targeting BRAF\, NGR1 fusions and HER2 with Kinnate Biopharmaceut
 icals\, Elevar Therapeutics and Boeringer Ingelheim.Harness the power of 
 the immune system to treat NSCLC by delving into the current best\, novel
  targets and combination strategies to improve patent outlook with Merck 
 &amp\; Co\, Immutep\, BerGenBio and Bristol-Myers Squibb.Advance the effi
 cacy of companion diagnostics and look to the future of early disease det
 ection\, application and differences in patient populations and how combi
 nation therapy can best be exploited to beat this drastically unmet clini
 cal need with UAMS\, Takeda\, Novartis\, BloodPAC and Amgen.\n\nThe Non-S
 mall Cell Lung Cancer Drug Development Summit features a deep-dive worksh
 op which explores utilizing EGFR-targeting in solid tumors outside of NSC
 LC with Maverick Therapeutics\, Black Diamond Therapeutics and Harvard Me
 dical School.\n
DTEND:20210715T180000
DTSTAMP:20260512T220333Z
DTSTART:20210713T080000
LOCATION:Online\, \,
SEQUENCE:0
SUMMARY:The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit is 
 the definitive industry-led forum for drug development in the largest sol
 id tumor...
UID:b296aca6-c9b4-437b-a2b0-4a0b5e8bbd74
END:VEVENT
END:VCALENDAR